Xeris forecasts $385M-$390M 2026 revenue as Recorlev expands and XP-8121 phase III start targets year end (NASDAQ:XERS)
· seekingalpha.com
Xeris Biopharma (XERS) Q2 2026 earnings call recap: record $92M revenue, Recorlev/Gvoke momentum, raised guidance to $385–$390M.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...